Get the Stockscreener App
25.57
3.91%
-1.05
Cg Oncology Inc stock is traded at $25.57, with a volume of 96,904.
It is down -3.91% in the last 24 hours and down -10.25% over the past month.
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
See More
Previous Close:
$26.62
Open:
$26.44
24h Volume:
96,904
Relative Volume:
0.14
Market Cap:
$1.99B
Revenue:
-
Net Income/Loss:
$-64.16M
P/E Ratio:
-20.13
EPS:
-1.2702
Net Cash Flow:
$-69.06M
1W Performance:
-5.22%
1M Performance:
-10.25%
6M Performance:
-26.49%
1Y Performance:
-35.71%
1-Day Range:
$25.46
$26.58
1-Week Range:
$25.46
$27.83
52-Week Range:
$24.16
$46.99
Cg Oncology Inc Stock (CGON) Company Profile
Name
Cg Oncology Inc
Sector
Industry
Phone
(949) 419-6203
Address
400 SPECTRUM CENTER DRIVE, IRVINE
Compare CGON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
25.50 | 1.99B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.82 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.62 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.88 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.54 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-23-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Jun-28-24 | Initiated | BofA Securities | Buy |
| Feb-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-24 | Initiated | Goldman | Neutral |
| Feb-20-24 | Initiated | Morgan Stanley | Overweight |
| Feb-14-24 | Initiated | H.C. Wainwright | Buy |
View All
Cg Oncology Inc Stock (CGON) Latest News
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates - The Manila Times
CG Oncology to Present Late-Breaking Abstract and Key Research on Cretostimogene Grenadenorepvec at 40th Annual EAU Congress - Nasdaq
Major Clinical Trial Results: CG Oncology Unveils New Bladder Cancer Treatment Data at European Congress - StockTitan
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Morgan Stanley - Defense World
3 Analysts Assess CG Oncology: What You Need To Know - Benzinga
Oncolytic Adenovirus Market Set to Grow Substantially Through 2032, DelveInsight Projects | CG Oncology, Orca Therapeutics B.V., Syneos Health, DNAtrix, Inc. - Barchart
Oncolytic Adenovirus Market Set to Grow Substantially Through - openPR
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug - Benzinga
New York State Common Retirement Fund Grows Stock Position in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Cg Oncology Inc (CGON) is looking forward to a strong quarter - SETE News
CG Oncology stock hits 52-week low at $24.15 amid challenges - Investing.com India
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Rhumbline Advisers - Defense World
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Can CG Oncology's CEO Presentation Reveal New Bladder Cancer Treatment Progress? - StockTitan
CG Oncology Enters Oversold Territory (CGON) - Nasdaq
CG Oncology stock hits 52-week low at $25.71 amid challenges - Investing.com Canada
Is CG Oncology, Inc. (CGON) An Oversold Biotech Stock to Buy Now? - Insider Monkey
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
IPOs Numbers Rise In 2024 But Dwindling Returns Could Diminish Potential In 2025 - Citeline News & Insights
Critical Analysis: Novozymes A/S (OTCMKTS:NVZMY) vs. CG Oncology (NASDAQ:CGON) - Defense World
Why CG Oncology, Inc. (CGON) is the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
Valneva (NASDAQ:VALN) and CG Oncology (NASDAQ:CGON) Head-To-Head Review - Defense World
UroGen Plots Expansion, Brings In A New Asset - Citeline News & Insights
Why CG Oncology (CGON) Is the Most Oversold Healthcare Stock to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Buy” by Analysts - Defense World
Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World
Mirae Asset Global Investments Co. Ltd. Buys Shares of 2,254 CG Oncology, Inc. (NASDAQ:CGON) - Defense World
China Universal Asset Management Co. Ltd. Acquires New Position in CG Oncology, Inc. (NASDAQ:CGON) - MarketBeat
Market Watch Highlights: Cg Oncology Inc (CGON) Ends on an Upturn Note at 30.32 - The Dwinnex
CGON Stock Sees Surge of Approximately 0.10% in Last Five Days - Knox Daily
CG Oncology, Inc. (NASDAQ:CGON) is a favorite amongst institutional investors who own 62% - Yahoo Finance
Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
CG Oncology, Inc. (NASDAQ:CGON) Stock Holdings Boosted by JPMorgan Chase & Co. - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Analysts Offer Predictions for CG Oncology FY2025 Earnings - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cantor Fitzgerald Comments on CG Oncology FY2025 Earnings - MarketBeat
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech - The Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA - openPR
This CG Oncology Insider Reduced Their Stake By 16% - Simply Wall St
Does CG Oncology, Inc. (CGON) Have the Potential to Rally 123.34% as Wall Street Analysts Expect? - MSN
Cg Oncology Inc (CGON) Volatility Hits 4.53%: What Good Investors Need To Be Aware Of - Stocks Register
Cg oncology director Leonard Post sells shares worth $29,660 By Investing.com - Investing.com Australia
Cg oncology director Leonard Post sells shares worth $29,660 - Investing.com India
CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 1,000 Shares - MarketBeat
Cg Oncology Inc Stock (CGON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cg Oncology Inc Stock (CGON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| POST LEONARD E | Director |
Feb 18 '25 |
Sale |
28.61 |
1,000 |
28,610 |
0 |
| POST LEONARD E | Director |
Jan 13 '25 |
Option Exercise |
0.60 |
1,000 |
600 |
1,000 |
| POST LEONARD E | Director |
Jan 13 '25 |
Sale |
29.66 |
1,000 |
29,660 |
0 |
| Song Hong Fang | Director |
Dec 16 '24 |
Sale |
28.00 |
700,000 |
19,600,000 |
3,003,931 |
| POST LEONARD E | Director |
Dec 16 '24 |
Option Exercise |
0.60 |
1,000 |
600 |
1,000 |
| POST LEONARD E | Director |
Dec 16 '24 |
Sale |
28.84 |
1,000 |
28,840 |
0 |
| POST LEONARD E | Director |
Dec 06 '24 |
Option Exercise |
0.60 |
1,000 |
600 |
1,000 |
| POST LEONARD E | Director |
Dec 06 '24 |
Sale |
34.54 |
1,000 |
34,542 |
0 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):